Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | BAX | Q07812 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28091759 | 0.95 | ESR2 (0.46) | MEN1KMT2AESR1ESR2LIPG | |
| SCHEMBL28452075 | 0.90 | SLC6A4 (0.45) | MEN1KMT2ALIPGAREGLN1 | |
| SCHEMBL21070833 | 0.89 | MEN1 (0.50) | MEN1KMT2AESR1ESR2PGR | |
| SCHEMBL15719318 | 0.89 | HTR2A (0.44) | MEN1KMT2AESR1ESR2LIPG | |
| SCHEMBL825065 | 0.88 | ESR1 (0.52) | MEN1KMT2AESR1ESR2PGR | |
| SCHEMBL446449 | 0.88 | AR (0.47) | MEN1KMT2ALIPGARACHE | |
| SCHEMBL2485652 | 0.86 | MEN1 (0.56) | MEN1KMT2AESR1ESR2PGR | |
| SCHEMBL14396811 | 0.85 | EGLN1 (0.46) | LIPGAREGLN1TP53TDP1 | |
| SCHEMBL6150468 | 0.85 | KMT2A (0.48) | MEN1KMT2AESR1ESR2LTA4H | |
| SCHEMBL10749041 | 0.84 | ESR1 (0.52) | MEN1KMT2AESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105211069-A | Fungicide penta benzene pyrrole bacterium amine blends | LANXESS DEUTSCHLAND GMBH | 2016-01-06 | — | — | CN | claimed |
| US-20140088041-A1 | FUNGICIDAL PENFLUFEN MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2014-03-27 | — | — | US | claimed |
| EP-2632267-A1 | FUNGICIDAL PENFLUFEN MIXTURES | Lanxess Deutschland GmbH (DE) | 2013-09-04 | — | — | EP | claimed |
| WO-2012076699-A1 | BIOCIDE MICROCAPSULE FORMULATIONS CONTAINING STABILISED IODINE-CONTAINING COMPOUNDS | LANXESS DEUTSCHLAND GMBH (DE) | 2012-06-14 | — | — | WO | claimed |
| EP-2462805-A1 | Formulations containing stabilised compounds containing iodine | LANXESS Deutschland GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| WO-2012055674-A1 | FUNGICIDAL PENFLUFEN MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2012-05-03 | — | — | WO | claimed |
| EP-2443928-A1 | Fungicide penflufen mixtures | LANXESS Deutschland GmbH (DE) | 2012-04-25 | — | — | EP | claimed |
| US-12604900-B2 | Penflufen as a wood preservative against wood- destroying basidiomy cetes | LANXESS DEUTSCHLAND GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-20260053140-A1 | Fungicide Mixtures | LANXESS DEUTSCHLAND GMBH (DE) | 2026-02-26 | — | — | US | disclosed |
| US-12369584-B2 | Fungicide mixtures | LANXESS DEUTSCHLAND GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| EP-3808178-B1 | FUNGICIDE MIXTURES | LANXESS DEUTSCHLAND GMBH (DE) | 2024-12-11 | — | — | EP | disclosed |
| US-20230337680-A1 | PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETES | LANXESS DEUTSCHLAND GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-3725155-B1 | ANTIFUNGAL WALLBOARDS | LANXESS DEUTSCHLAND GMBH (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-1569920-A2 | CYCLOPENTA C]ISOXAZOLE-3-AMINES USED AS PROTECTIVE AGENTS FOR MATERIALS | LANXESS Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569894-A2 | 2-OXYAMINO-1-CYCLOPENTENE-1-NITRILES AS MATERIAL PROTECTIVE AGENTS | LANXESS Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1527054-A1 | SUBSTITUTED THIAZINES AS MATERIAL PROTECTING AGENTS | Lanxess Deutschland GmbH (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004050644-A2 | CYCLOPENTA[C]ISOXAZOLE-3-AMINES USED AS PROTECTIVE AGENTS FOR MATERIALS | LANXESS DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050608-A2 | 2-OXYAMINO-1-CYCLOPENTENE-1-NITRILES AS MATERIAL PROTECTIVE AGENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004013113-A1 | SUBSTITUTED THIAZINES AS MATERIAL PROTECTING AGENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003005823-A2 | BROMONITROTHIENYLDIOXANS | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337680-A1 | PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETES | BLVRB, DCXR, PAH | MEN1 1024/4885KMT2A 2754/4885ESR1 1778/4885 |
| US-20140088041-A1 | FUNGICIDAL PENFLUFEN MIXTURES | CYP3A43, CYP2F1, CYP4F3 | MEN1 892/4885KMT2A 1964/4885ESR1 1878/4885 |
| US-12604900-B2 | Penflufen as a wood preservative against wood- destroying basidiomy cetes | PSENEN, CMA1, PSEN1 | MEN1 1445/4885KMT2A 2941/4885ESR1 2232/4885 |
| US-20260053140-A1 | Fungicide Mixtures | TTL, MASTL, CYP51A1 | MEN1 1036/4885KMT2A 1480/4885ESR1 4571/4885 |
| US-12369584-B2 | Fungicide mixtures | TTL, TH, DDT | MEN1 1395/4885KMT2A 1365/4885ESR1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.